Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis

Atherosclerosis

Volumn 208, Issue 2, 2010, Pages 484-489

  Drexel, Heinz ^a,b,c,d   Aczel, Stefan ^a,b   Marte, Thomas ^a,b   Vonbank, Alexander ^a,c   Saely, Christoph H ^a,b,c  

^a Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^b Academic Teaching Hospital Feldkirch   (Austria)

^c University for Human Sciences   (Liechtenstein)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Coronary artery disease; Diabetes; HDL cholesterol; Prognosis; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; TRIGLYCERIDES;

EID: 75049085655     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.08.026     Document Type: Article

References (24)

1. McEwen L.N., Kim C., Karter A.J., et al. Risk factors for mortality among patients with diabetes: the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care 30 (2007) 1736-1741
2. Cefalu W.T. Glycemic targets and cardiovascular disease. N Engl J Med 358 (2008) 2633-2635
3. Dluhy R.G., and McMahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358 (2008) 2630-2633
4. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
5. Shepherd J., Barter P., Carmena R., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29 (2006) 1220-1226
6. Castelli W.P., Garrison R.J., Wilson P.W., et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256 (1986) 2835-2838
7. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
8. Amarenco P., Goldstein L.B., Callahan III A., et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis 204 (2009) 515-520
9. Saely C.H., Aczel S., Marte T., et al. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 90 (2005) 5698-5703
10. Drexel H., Amann F.W., Beran J., et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 90 (1994) 2230-2235
11. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
12. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
13. Drexel H., Aczel S., Marte T., et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?. Diabetes Care 28 (2005) 101-107
14. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
15. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46 (2003) 733-749
16. Schaefer E.J., and Asztalos B.F. The effects of statins on high-density lipoproteins. Curr Atheroscler Rep 8 (2006) 41-49
17. Hoefle G., Saely C.H., Aczel S., et al. Impact of total and central obesity on vascular mortality in patients undergoing coronary angiography. Int J Obes (Lond) 29 (2005) 785-791
18. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
19. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
20. AIM HIGH: Niacin Plus Statin to Prevent Vascular Events. www.clinicaltrials.gov, 2009 (accessed 07.07.09).
21. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. www.clinicaltrials.gov, 2009 (accessed 07.07.09).
22. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
23. Ginsberg H.N., Bonds D.E., Lovato L.C., et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99 (2007) 56i-67i
24. Tall A.R., Yvan-Charvet L., and Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 27 (2007) 257-260